These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 1328819

  • 1. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
    Mizuno K, Kato N, Matsubara A, Nakano K, Kurono M.
    Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
    [Abstract] [Full Text] [Related]

  • 2. Effect of long-term treatment with a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2',5'-dioxospiro-[chroman-4,4'-imidazolidine]-2-carbox amide (SNK-860), on peripheral neuropathy in streptozotocin-induced diabetic rats.
    Kato N, Mizuno K, Matsubara A, Nakano K, Kurono M, Yagihashi S.
    J Diabetes Complications; 1994 Oct; 8(1):27-32. PubMed ID: 8167384
    [Abstract] [Full Text] [Related]

  • 3. Effect of a new aldose reductase inhibitor, 8'-chloro-2',3'-dihydrospiro [pyrrolidine-3,6'(5'H)-pyrrolo[1,2,3-de] [1,4]benzoxazine]-2,5,5'- trione (ADN-138), on delayed motor nerve conduction velocity in streptozotocin-diabetic rats.
    Hirata Y, Fujimori S, Okada K.
    Metabolism; 1988 Feb; 37(2):159-63. PubMed ID: 2828821
    [Abstract] [Full Text] [Related]

  • 4. Polyol pathway, 2,3-diphosphoglycerate in erythrocytes and diabetic neuropathy in rats.
    Nakamura J, Koh N, Sakakibara F, Hamada Y, Wakao T, Hara T, Mori K, Nakashima E, Naruse K, Hotta N.
    Eur J Pharmacol; 1995 Dec 27; 294(1):207-14. PubMed ID: 8788433
    [Abstract] [Full Text] [Related]

  • 5. Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
    Hotta N, Kakuta H, Fukasawa H, Koh N, Sakakibara F, Nakamura J, Hamada Y, Wakao T, Hara T, Mori K.
    Diabetes Res Clin Pract; 1995 Feb 27; 27(2):107-17. PubMed ID: 7607048
    [Abstract] [Full Text] [Related]

  • 6. Reduced motor nerve conduction velocity and Na(+)-K(+)-ATPase activity in rats maintained on L-fucose diet. Reversal by myo-inositol supplementation.
    Yorek MA, Wiese TJ, Davidson EP, Dunlap JA, Stefani MR, Conner CE, Lattimer SA, Kamijo M, Greene DA, Sima AA.
    Diabetes; 1993 Oct 27; 42(10):1401-6. PubMed ID: 8397126
    [Abstract] [Full Text] [Related]

  • 7. Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition.
    Gillon KR, Hawthorne JN, Tomlinson DR.
    Diabetologia; 1983 Oct 27; 25(4):365-71. PubMed ID: 6416913
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A combination of the aldose reductase inhibitor, statil, and the prostaglandin E1 analogue, OP1206.alpha CD, completely improves sciatic motor nerve conduction velocity in streptozocin-induced chronically diabetic rats.
    Yasuda H, Sonobe M, Hisanaga T, Kawabata T, Maeda K, Kikkawa R, Shigeta Y.
    Metabolism; 1992 Jul 27; 41(7):778-82. PubMed ID: 1320179
    [Abstract] [Full Text] [Related]

  • 11. A sodium-pump defect in diabetic peripheral nerve corrected by sorbinil administration: relationship to myo-inositol metabolism and nerve conduction slowing.
    Greene DA.
    Metabolism; 1986 Apr 27; 35(4 Suppl 1):60-5. PubMed ID: 2421135
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Action of sorbinil in diabetic peripheral nerve. Relationship of polyol (sorbitol) pathway inhibition to a myo-inositol-mediated defect in sodium-potassium ATPase activity.
    Greene DA, Lattimer SA.
    Diabetes; 1984 Aug 27; 33(8):712-6. PubMed ID: 6086432
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Decreased myo-inositol content and Na+-K+-ATPase activity in superior cervical ganglion of STZ-diabetic rat and prevention by aldose reductase inhibition.
    Greene DA, Mackway AM.
    Diabetes; 1986 Oct 27; 35(10):1106-8. PubMed ID: 3019804
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. An aldose reductase inhibitor but not myo-inositol blocks enhanced polyphosphoinositide turnover in peripheral nerve from diabetic rats.
    Berti-Mattera L, Day N, Peterson RG, Eichberg J.
    Metabolism; 1996 Mar 27; 45(3):320-7. PubMed ID: 8606638
    [Abstract] [Full Text] [Related]

  • 18. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat.
    Stevens MJ, Lattimer SA, Kamijo M, Van Huysen C, Sima AA, Greene DA.
    Diabetologia; 1993 Jul 27; 36(7):608-14. PubMed ID: 8359577
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism.
    Cameron NE, Cotter MA, Dines KC, Maxfield EK, Carey F, Mirrlees DJ.
    Diabetologia; 1994 Jul 27; 37(7):651-63. PubMed ID: 7958535
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.